• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Pharma 2023: Working with Patient Advocacy Groups

Article

Rebecca Vermeulen, VP Global Patient Networks, Product Development Medical Affairs for Roche discusses how they approach patient engagement.

Rebecca Vermeulen, VP Global Patient Networks, Product Development Medical Affairs for Roche discusses how the role of patient advocacy groups to improve patient engagement, how Roche organizes their relationships and the key takeaways for industry professionals.

Related Videos
Related Content
Say Hello to Flexible: Reimagining the Patient Journey

Say Hello to Flexible: Reimagining the Patient Journey

April 15th 2024
Article

Through embracing connected and tech-enabled services and devices, new avenues and opportunities exist for greater clinical trial flexibility in drug research.

Positioning Medical Information as a Trust Driver for Your Brand

Positioning Medical Information as a Trust Driver for Your Brand

March 12th 2024
Article

Four steps to maximize the impact of medical information services as an engagement gateway.

Beyond Medicines: Pharma's Journey with Patient Family Advisory Councils

Beyond Medicines: Pharma's Journey with Patient Family Advisory Councils

February 1st 2024
Article

Including patient and family feedback in our discussions will help shape our understanding of their perception of provided care and services and how we operate as a whole.

Image credit: Design Cells | stock.adobe.com

Novartis' Lutathera Shows Significant Survival Benefit as First-Line Treatment for GEP-NETs

January 19th 2024
Article

Lutathera plus long-acting release octreotide lowered the risk of disease progression or death by 72% in patients with somatostatin receptor-positive well-differentiated grade 2/3 advanced gastroenteropancreatic neuroendocrine tumors.

Eisai

Eisai To Present New Data For Gastrointestinal Cancer Research at ASCO GI 2024

January 17th 2024
Article

The data was collected during the LEAP clinical program, developed in partnership with Merck.

Image credit: Lucky Ai | stock.adobe.com

Presentation at J.P. Morgan Healthcare Conference Highlights Growth of Platform for AI, Data

January 15th 2024
Article

Ginkgo Bioworks announces projected total revenue of $250–$260 million for 2023 for large scale data generation and artificial intelligence for biopharma R&D.